Madrigal Pharmaceuticals Inc (MDGL)
229.84
+13.79
(+6.38%)
USD |
NASDAQ |
May 03, 16:00
229.49
-0.35
(-0.15%)
After-Hours: 20:00
Madrigal Pharmaceuticals Enterprise Value: 4.055B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 4.055B |
May 02, 2024 | 3.780B |
May 01, 2024 | 3.672B |
April 30, 2024 | 3.541B |
April 29, 2024 | 3.482B |
April 26, 2024 | 3.328B |
April 25, 2024 | 3.349B |
April 24, 2024 | 3.553B |
April 23, 2024 | 3.827B |
April 22, 2024 | 3.729B |
April 19, 2024 | 3.700B |
April 18, 2024 | 3.904B |
April 17, 2024 | 4.025B |
April 16, 2024 | 4.117B |
April 15, 2024 | 4.085B |
April 12, 2024 | 4.189B |
April 11, 2024 | 4.362B |
April 10, 2024 | 4.350B |
April 09, 2024 | 4.443B |
April 08, 2024 | 4.429B |
April 05, 2024 | 4.317B |
April 04, 2024 | 4.286B |
April 03, 2024 | 4.361B |
April 02, 2024 | 4.346B |
April 01, 2024 | 4.570B |
Date | Value |
---|---|
March 28, 2024 | 4.795B |
March 27, 2024 | 4.631B |
March 26, 2024 | 4.408B |
March 25, 2024 | 4.408B |
March 22, 2024 | 4.420B |
March 21, 2024 | 4.561B |
March 20, 2024 | 4.635B |
March 19, 2024 | 4.768B |
March 18, 2024 | 5.117B |
March 15, 2024 | 4.861B |
March 14, 2024 | 4.328B |
March 13, 2024 | 4.913B |
March 12, 2024 | 4.708B |
March 11, 2024 | 4.658B |
March 08, 2024 | 4.562B |
March 07, 2024 | 4.476B |
March 06, 2024 | 4.603B |
March 05, 2024 | 4.426B |
March 04, 2024 | 4.387B |
March 01, 2024 | 4.488B |
February 29, 2024 | 4.181B |
February 28, 2024 | 4.540B |
February 27, 2024 | 4.253B |
February 26, 2024 | 4.109B |
February 23, 2024 | 4.188B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
519.25M
Minimum
Apr 03 2020
5.459B
Maximum
Apr 28 2023
1.961B
Average
1.291B
Median
Jun 19 2020
Enterprise Value Benchmarks
Eli Lilly and Co | 722.23B |
Viking Therapeutics Inc | 7.524B |
Akero Therapeutics Inc | 830.46M |
89bio Inc | 323.90M |
Geron Corp | 1.971B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -112.19M |
Total Expenses (Quarterly) | 117.18M |
EPS Diluted (Quarterly) | -5.72 |
Earnings Yield | -8.69% |
Normalized Earnings Yield | -15.23 |